Prior to the 1906 establishment of the US pharmacopeia drug information was related by

1. Generic Drugs.//www.who.int/trade/glossary/story034/en/index.html,

2. Birkett DJ: Generics – equal or not?. Aust Prescr. 2003, 26 (4): 85-87.

   Article  Google Scholar 

3. FDA basics - Drugs.//www.fda.gov/AboutFDA/Transparency/Basics/ucm192696.htm,

4. Approval of Generic Drugs.//www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm127615.pdf,

5. Understanding Generic Drugs.//www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/default.htm,

6. Hatch-Waxman Act summary [Drug Price Competition and Patent Term Restoration Act of. 1984,//thomas.loc.gov/cgi-bin/bdquery/z?d098:SN01538:@@@L&summ2=m&, ],

7. Office of Generic Drugs presentation.//www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM226568.pdf,

8. Generic Drugs: Overview of ANDA Review Process.//www.fda.gov/downloads/Drugs/NewsEvents/UCM167310.pdf,

9. Simoens S: International comparison of generic medicine prices. Curr Med Res Opin. 2007, 23 (11): 2647-2654. 10.1185/030079907X233395.

   Article  PubMed  Google Scholar 

10. What Are Generic Drugs?.//www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm144456.htm,

11. US-FDA: Guidance for Industry - Bioavailability and Bioequivalence. FDA Guidances for Industry.

12. Process for Approving Generic Drugs.//www.fda.gov/Training/ForHealthProfessionals/ucm090215.htm,

13. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH: Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008, 300 (21): 2514-2526. 10.1001/jama.2008.758.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

14. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J: Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. Ann Pharmacother. 2009, 43 (10): 1583-1597. 10.1345/aph.1M141.

    CAS  Article  PubMed  Google Scholar 

15. Patel V, Cordato DJ, Dias M, Beran RG: Changed constitution without change in brand name–the risk of generics in epilepsy. Epilepsy Res. 2012, 98 (2–3): 269-272.

    Article  PubMed  Google Scholar 

16. EMA Q&A on Generic Medicine.//www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500012382.pdf,

17. EU Authorisation Procedures.//ec.europa.eu/health/authorisation-procedures_en.htm,

18. The Centralised Procedure.//ec.europa.eu/health/authorisation-procedures-centralised_en.htm,

19. The Mutual Recognition Procedure.//ec.europa.eu/health/authorisation-procedures-mutual-recognition_en.htm,

20. The Decentralised Procedure.//ec.europa.eu/health/authorisation-procedures-decentralised_en.htm,

21. Directive. 2001,//eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32001L0083:EN:HTML, /83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use,

22. Notice to Applicants Volume 2A Procedures for marketing authorisation.//ec.europa.eu/health/files/eudralex/vol-2/a/vol2a_chap1_2005-11_en.pdf,

23. Marketing Authorisation Process for Generic Medicines.//198.170.119.137/gen-authorisation.htm,

24. Committee For Medicinal Products For Human Use: European Medicines Agency website. 2010, Guideline on the Investigation of Bioequivalence, European Medicines Agency

    Google Scholar 

25. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A: Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010, 10 (1): 73-85. 10.1586/erp.09.73.

    Article  PubMed  Google Scholar 

26. Dylst P, Vulto A, Simoens S: The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res. 2011, 11 (6): 729-737. 10.1586/erp.11.70.

    Article  PubMed  Google Scholar 

27. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M: Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010, 10 (6): 707-722. 10.1586/erp.10.72.

    Article  PubMed  Google Scholar 

28. Puig-Junoy J: Impact of European pharmaceutical price regulation on generic price competition: a review. PharmacoEconomics. 2010, 28 (8): 649-663. 10.2165/11535360-000000000-00000.

    Article  PubMed  Google Scholar 

29. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, Garuolienè K, Kalaba M, Laius O, Joppi R: Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals. 2010, 3 (8): 2470-2494. 10.3390/ph3082470.

    Article  PubMed Central  Google Scholar 

30. Simoens S: Generic medicine pricing in Europe: current issues and future perspective. J Med Econ. 2008, 11 (1): 171-175. 10.3111/13696990801939716.

    Article  PubMed  Google Scholar 

31. European Generic Medicines Association - Healthcare Economics.//198.170.119.137/gen-economics.htm,

32. Why do medications have brand names and generic names?.//www.nhs.uk/chq/Pages/1003.aspx?CategoryID=73&SubCategoryID=108,

33. Sinclair U: The Jungle. 1906, Doubleday, Jabber & Compan

    Google Scholar 

34. 100 Years of Protecting and Promoting Women's Health.//www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118458.htm,

35. Milestones in U.S. Food and Drug Law History.//www.fda.gov/AboutFDA/WhatWeDo/History/Milestones/default.htm,

36. What Are "Biologics" Questions and Answers.//www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm,

37. Biosimilars.//www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm,

38. Official Journal of the European Union. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. 1965, Eur-Lex: The Council Of The European Communities

39. Pharmaceuticals In The European Union.//ec.europa.eu/enterprise/newsroom/cf/_getdocument.cfm?doc_id=1684,

40. Official Journal of the European Union. Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products. 1975, Eur-Lex: The Council Of The European Communities

41. Official Journal of the European Union. Second Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. 1975, Eur-Lex: The Council Of The European Communities

42. Official Journal of the European Union. Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. 1993, Eur-Lex: The Council Of The European Communities

43. Official Journal of the European Union. Council Directive 93/41/EEC of 14 June 1993 repealing Directive 87/22/EEC on the approximation of national measures relating to the placing on the market of high- technology medicinal products, particularly those derived from biotechnology. 1993, Eur-Lex: The Council Of The European Communities

44. New visual identity, web/e-mail addresses and organisation chart of the European Medicines Agency.//www.epha.org/IMG/pdf/EMEA_Communication_NewVisiualIdentity_en.pdf,

45. Directive. 2011,//ec.europa.eu/health/files/eudralex/vol-1/dir_2011_62/dir_2011_62_en.pdf, /62/EU Of The European Parliament And Of The Council Of 8 June 2011 Amending Directive 2001/83/EC On The Community Code Relating To Medicinal Products For Human Use, As Regards The Prevention Of The Entry Into The Legal Supply Chain Of Falsified Medicinal Products,

46. Falsified medicines.//ec.europa.eu/health/human-use/falsified_medicines/index_en.htm,

47. FAQ on Biosimilar Medicines.//www.egagenerics.com/index.php/biosimilar-medicines/faq-on-biosimilars,

48. Questions and Answers on biosimilar medicines (similar biological medicinal products).//www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf,

49. European Public Assessment Reports.//www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&murl=menus%2Fmedicines%2Fmedicines.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit&jsenabled=true,

50. DiMasi JA, Grabowski HG: The cost of biopharmaceutical R&D: is biotech different?. Manag Decis Econ. 2007, 28 (4–5): 469-479.

    Article  Google Scholar 

51. DiMasi J: Risks in new drug develoopment: Approval success rates for investigational drugs. Clin Pharmacol Ther. 2001, 69 (5): 297-307. 10.1067/mcp.2001.115446.

    CAS  Article  PubMed  Google Scholar 

52. New Drug Development and Review Process.//www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm053131.htm,

53. Guidance on the establishment of new INN stems.//www.who.int/medicines/services/inn/StemBook_2011_Final.pdf,

54. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH: Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs: A Systematic Review and Meta-Analysis. Drugs. 2010, 70 (5): 605-621. 10.2165/10898530-000000000-00000. 610.2165/10898530-000000000-000000000

    CAS  Article  PubMed  PubMed Central  Google Scholar 

55. Amit G, Rosen A, Wagshal AB, Bonneh DY, Liss T, Grosbard A, Ilia R, Katz A: Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. Am J Cardiol. 2004, 93 (12): 1558-1560. 10.1016/j.amjcard.2004.02.071.

    CAS  Article  PubMed  Google Scholar 

56. Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A: Generic olanzapine: health authority opportunity or nightmare?. Expert Rev Pharmacoecon Outcomes Res. 2008, 8 (6): 549-555. 10.1586/14737167.8.6.549.

    Article  PubMed  Google Scholar 

57. Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM: Evaluation of an interchangeability switch in patients treated with clozapine: A retrospective review. J Clin Psychiatr. 2006, 67 (7): 1047-1054. 10.4088/JCP.v67n0706.

    CAS  Article  Google Scholar 

58. Paton C: Generic clozapine: outcomes after switching formulations. Br J Psychiatr J Mental Sci. 2006, 189: 184-185. 10.1192/bjp.bp.105.017079.

    Article  Google Scholar 

59. Bulsara C, McKenzie A, Sanfilippo F, Holman CDJ, Emery JE: ‘Not the full Monty’: a qualitative study of seniors’ perceptions of generic medicines in Western Australia. Aust J Prim Health. 2010, 16 (3): 240-245. 10.1071/PY10006.

    Article  PubMed  Google Scholar 

60. Hassali MAA, Shafie AA, Jamshed S, Ibrahim MIM, Awaisu A: Consumers' views on generic medicines: A review of the literature. Int J Pharm Pract. 2009, 17 (2): 79-88.

    PubMed  Google Scholar 

61. Figueiras MJ, Cortes MA, Marcelino D, Weinman J: Lay views about medicines: the influence of the illness label for the use of generic versus brand. Psychol Health. 2010, 25 (9): 1121-1128. 10.1080/08870440903137170.

    Article  PubMed  Google Scholar 

62. Babar ZU, Grover P, Stewart J, Hogg M, Short L, Seo HG, Rew A: Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand. Res Soc Admin Pharm RSAP. 2011, 7 (3): 294-305. 10.1016/j.sapharm.2010.06.004.

    Article  Google Scholar 

63. Quintal C, Mendes P: Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Pol (Amsterdam, Netherlands). 2012, 104 (1): 61-68. 10.1016/j.healthpol.2011.10.001.

    Article  Google Scholar 

64. Heikkila R, Mantyselka P, Ahonen R: Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011, 20 (2): 185-191. 10.1002/pds.2084.

    Article  PubMed  Google Scholar 

65. Heikkila R, Mantyselka P, Ahonen R: Price, familiarity, and availability determine the choice of drug - a population-based survey five years after generic substitution was introduced in Finland. BMC Clin Pharmacol. 2011, 11: 20-10.1186/1472-6904-11-20.

    Article  PubMed  PubMed Central  Google Scholar 

66. Graedon J, Graedon T: Are Generic Drugs Safe?. Prevention (Emmaus, Pa). 2008, 175: 173-174.//www.prevention.com/health/healthy-living/find-out-how-use-generic-drugs-safely,

    Google Scholar 

67. Ringe JD, Moller G: Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. 2009, 30 (2): 213-221. 10.1007/s00296-009-0940-5.

    CAS  Article  PubMed  Google Scholar 

68. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C: A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int J Established Result Cooperat Between Eur Found Osteoporos Nat Osteoporos Found USA. 2012, 23 (1): 213-221. 10.1007/s00198-011-1796-6.

    CAS  Article  Google Scholar 

69. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA: Treatment failure in osteoporosis. Osteoporos Int J Established Result Cooperat Between Eur Found Osteoporos Nat Osteoporos Found USA. 2012, 23 (12): 2769-2774. 10.1007/s00198-012-2093-8.

    CAS  Article  Google Scholar 

70. Privitera MD: Generic Antiepileptic Drugs: Current Controversies and Future Directions. Epilepsy Curr. 2008, 8 (5): 113-117. 10.1111/j.1535-7511.2008.00261.x.

    Article  PubMed  PubMed Central  Google Scholar 

71. Jain K: Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. J R Soc Med. 1993, 86 (3): 133-136.

    CAS  PubMed  PubMed Central  Google Scholar 

72. Mayer T, May TW, Altenmuller DM, Sandmann M, Wolf P: Clinical Problems with Generic Antiepileptic Drugs: Comparison of Sustained-Release Formulations of Carbamazepine. Clin Drug Investig. 1999, 18 (1): 17-26. 10.2165/00044011-199918010-00003.

    CAS  Article  Google Scholar 

73. Crawford P, Feely M, Guberman A, Kramer G: Are there potential problems with generic substitution of antiepileptic drugs?: A review of issues. Seizure. 2006, 15 (3): 165-176. 10.1016/j.seizure.2005.12.010.

    CAS  Article  PubMed  Google Scholar 

74. Ferner RE, Lenney W, Marriott JF: Controversy over generic substitution. BMJ (Clin Res ed). 2010, 340: c2548-10.1136/bmj.c2548.

    CAS  Article  Google Scholar 

75. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK: Physician perceptions about generic drugs. Ann Pharmacother. 2011, 45 (1): 31-38. 10.1345/aph.1P389.

    Article  PubMed  Google Scholar 

76. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK: Patients' perceptions of generic medications. Health Aff (Millwood). 2009, 28 (2): 546-556. 10.1377/hlthaff.28.2.546.

    Article  Google Scholar 

77. Talati R, Scholle JM, Phung OP, Baker EL, Baker WL, Ashaye A, Kluger J, Coleman CI, White CM: Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Pharmacotherapy. 2012, 32 (4): 314-322. 10.1002/j.1875-9114.2012.01099.x.

    CAS  Article  PubMed  Google Scholar 

78. Johnston A: Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr Med Res Opin. 2010, 26 (4): 871-878. 10.1185/03007990903578462.

    CAS  Article  PubMed  Google Scholar 

79. Johnston A, Stafylas P, Stergiou GS: Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010, 70 (3): 320-334. 10.1111/j.1365-2125.2010.03681.x.

    Article  PubMed  PubMed Central  Google Scholar 

80. Duerden MG, Hughes DA: Generic and therapeutic substitutions in the UK: are they a good thing?. Br J Clin Pharmacol. 2010, 70 (3): 335-341. 10.1111/j.1365-2125.2010.03718.x.

    Article  PubMed  PubMed Central  Google Scholar 

81. Simoens S: Generic and therapeutic substitution: ethics meets health economics. Int J Clin Pharm. 2011, 33 (3): 469-470. 10.1007/s11096-011-9500-7.

    Article  PubMed  Google Scholar 

82. Johnston A, Asmar R, Dahlof B, Hill K, Jones DA, Jordan J, Livingston M, Macgregor G, Sobanja M, Stafylas P: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. Br J Clin Pharmacol. 2011, 72 (5): 727-730. 10.1111/j.1365-2125.2011.03987.x.

    Article  PubMed  PubMed Central  Google Scholar 

83. Fusier I, Tollier C, Husson MC: Medicines containing pharmaceutical excipients with known effects: a French review. Pharm World Sci PWS. 2003, 25 (4): 152-155. 10.1023/A:1024815412228.

    CAS  Article  PubMed  Google Scholar 

84. Mumoli N, Cei M, Luschi R, Carmignani G, Camaiti A: Allergic reaction to Croscarmellose sodium used as excipient of a generic drug. QJM. 2011, 104 (8): 709-710. 10.1093/qjmed/hcq175.

    CAS  Article  PubMed  Google Scholar 

85. Reiffel JA: Formulation Substitution and Other Pharmacokinetic Variability: Underappreciated Variables Affecting Antiarrhythmic Efficacy and Safety in Clinical Practice. Am J Cardiol. 2000, 85: 46D-52D. 10.1016/S0002-9149(00)00906-1.

    CAS  Article  PubMed  Google Scholar 

86. Coloe J, Zirwas MJ: Allergens in corticosteroid vehicles. Dermatitis Contact Atopic Occup Drug Offic J Am Contact Dermatitis Soc North American Contact Dermatitis Group. 2008, 19 (1): 38-42.

    Google Scholar 

87. Laroche ML, Traore H, Merle L, Gaulier JM, Viana M, Preux PM: Quality of phenobarbital solid-dosage forms in the urban community of Nouakchott (Mauritania). Epilepsia. 2005, 46 (8): 1293-1296. 10.1111/j.1528-1167.2005.01805.x.

    Article  PubMed  Google Scholar 

88. Fauci AS, Harrison TR: Harrison's principles of internal medicine. 2008, New York; London: McGraw-Hill Medical

    Google Scholar 

89. Generic substitution terminated for oral medicines containing cyclosporine or tacrolimus.//laegemiddelstyrelsen.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/news/generic-substitution-terminated-for-oral--tacrolimus,

90. British Medical Association and the Royal Pharmaceutical Society of Great Britain: British National Formulary. 2012, BMJ Publishing Group, 63

91. Items Unsuitable for Generic Prescribing.//www.nhssb.n-i.nhs.uk/prescribing/documents/RegionalListGenericExceptionsJul08.pdf,

92. OECD Health Data. 2012,//www.oecd.org/health/healthpoliciesanddata/oecdhealthdata2012-frequentlyrequesteddata.htm, - Frequently Requested Data,

93. Delivery of Pharmaceuticals in Ireland – Getting a Bigger Bang for the Buck.//www.esri.ie/UserFiles/publications/RS24.pdf,

94. Generic Market Shares in Europe. 2006,//198.170.119.137/doc/fac-GxMktEur_2006.pdf,

95. Economies in Drug Usage in the Irish Healthcare Setting.//www.dohc.ie/publications/pdf/economies_drug_usage.pdf?direct=1,

96. Generic Drug Utilisation In Ireland In. 2008,//www.ncpe.ie/u_docs/doc_163.pdf,

97. Finance Shared Services Primary Care Reimbursement Service: Statistical Analysis Of Claims And Payments. 2007,//www.hse.ie/eng/Staff/PCRS/PCRS_Publications/2007_Report.pdf,

98. Tilson L, O'Leary A, Usher C, Barry M: Pharmacoeconomic Evaluation in Ireland. PharmacoEconomics. 2010, 28 (4): 307-322. 10.2165/11318790-000000000-00000.

    Article  PubMed  Google Scholar 

99. Tilson L, McGowan B, Ryan M, Barry M: Generic Drug Utilisation on the General Medical Services (GMS) Scheme in 2001. Ir Med J. 2003, 96 (6): 176-179.

    CAS  PubMed  Google Scholar 

100. Generic Prescribing.//www.stjames.ie/GPsHealthcareProfessionals/Newsletters/NMICBulletins/NMICBulletins2009/GenericbulletinNMICv15No1webwithefs.pdf,

101. Gatyas G: IMS Institute Reports U.S. Spending on Medicines Grew 2.3 Percent in 2010, to $307.4 Billion. In: IMS Institute for Healthcare Informatics. IMS Website. 2011

     Google Scholar 

102. Prescriptions Dispensed in the Community: England, Statistics for. 2000,//www.ic.nhs.uk/webfiles/publications/007_Primary_Care/Prescribing/Prescriptionsdispensedinthecommunity2000-2010/Prescriptions_Dispensed_2000_2010.pdf, to 2010,

103. Bennie M, Godman B, Bishop I, Campbell S: Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012, 12 (1): 125-130. 10.1586/erp.11.98.

     Article  PubMed  Google Scholar 

104. Godman B, Abuelkhair M, Vitry A, Abdu S: Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI. 2012, 1 (2): 21-35.

     Google Scholar 

105. Generic Drug Savings In The U.S. (Fourth Annual Edition. 2012,//www.gphaonline.org/sites/default/files/IMSStudyAug2012WEB.pdf,

106. Generic Pharmaceutical Association: New Study Finds Use of Generic Prescription Drugs Saved Consumers and the U.S. Health Care System $931 Billion Over Past 10 Years. 2011, Generic Pharmacetical Association. GhPa online

     Google Scholar 

107. Proposed Model for Reference Pricing and Generic Substitution.//www.dohc.ie/publications/pdf/reference_pricing_generic_substitution.pdf?direct=1,

108. Kanavos P: Do generics offer significant savings to the UK National Health Service?. Curr Med Res Opin. 2007, 23 (1): 105-116. 10.1185/030079907X159506.

     Article  PubMed  Google Scholar 

109. Kanavos P, Taylor D: Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?. Curr Med Res Opin. 2007, 23 (10): 2467-2476. 10.1185/030079907X219571.

     Article  PubMed  Google Scholar 

110. Kanavos P, Costa-Font J, Seeley E: Competition in off-patent drug markets: Issues, regulation and evidence. Econ Pol. 2008, 23 (55): 499-544. 10.1111/j.1468-0327.2008.00207.x.

     Article  Google Scholar 

111. Chandra A, Gruber J, McKnight R: Patient Cost-Sharing and Hospitalization Offsets in the Elderly. Am Econ Rev. 2010, 100 (1): 193-213. 10.1257/aer.100.1.193.

     Article  PubMed  PubMed Central  Google Scholar 

112. IPHA Statement on the report on a Proposed Model for Reference Pricing and Generic Substitution.//www.ipha.ie/news/latest-news.aspx?page=3&article=bfe9dcd0-7ae8-4f11-989a-875322ee8bc7,

113. Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A: European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011, 11 (3): 343-349. 10.1586/erp.11.24.

     Article  PubMed  Google Scholar 

114. Barron D: Concerns about generic substitution. Irish Medical News. 2011, 28: 1-

     Google Scholar 

115. Hassali MA, Kong DCM, Stewart K: Utilisation of generic medicines in the Australian healthcare system. J Generic Med. 2004, 2 (1): 42-52. 10.1057/palgrave.jgm.4940051.

     Article  Google Scholar 

116. Scuderi M: Generic substitution in a Brisbane community pharmacy. Aust Pharm. 2002, 21: 116-121.

     Google Scholar 

117. Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K: What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005, 14 (5): 341-348. 10.1002/pds.1055.

     Article  PubMed  Google Scholar 

118. Andersson KA, Petzold MG, Allebeck P, Carlsten A: Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. BMC Health Serv Res. 2008, 8: 50-10.1186/1472-6963-8-50.

     Article  PubMed  PubMed Central  Google Scholar 

119. Andersson K, Bergstrom G, Petzold MG, Carlsten A: Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Health Pol (Amsterdam, Netherlands). 2007, 81 (2–3): 376-384.

     Article  Google Scholar 

120. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V: Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. PharmacoEconomics. 2008, 26 (7): 537-550. 10.2165/00019053-200826070-00001.

     Article  PubMed  Google Scholar 

121. Banahan BF, Kolassa EM: A Physician Survey on Generic Drugs and Substitution of Critical Dose Medications. Arch Intern Med. 1997, 157 (18): 2080-2088. 10.1001/archinte.1997.00440390066010.

     Article  PubMed  Google Scholar 

122. Kirking DM, Gaither CA, Ascione FJ, Welage LS: Physicians’ individidual and organizational views on generic medications. J Am Pharm Assoc. 2001, 41 (5): 718-722.

     Article  Google Scholar 

123. Shrank WH, Stedman M, Ettner SL, DeLapp D, Dirstine J, Brookhart MA, Fischer MA, Avorn J, Asch SM: Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J Gen Intern Med. 2007, 22 (9): 1298-1304. 10.1007/s11606-007-0284-3.

     Article  PubMed  PubMed Central  Google Scholar 

124. Feely J, McGettigan P, O'Shea B, Chan R, McManus J: Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: Prescribers’ concerns. Ir Med J. 1997, 90 (4): 146-147.

     PubMed  Google Scholar 

125. Murphy MB: Review of Indicative Drug Target Savings Scheme. In: Review of Indicative Drug Target Savings Scheme. 1997, Lenus website: Health Service Executive

     Google Scholar 

126. Practice Managers Manual.//www.lenus.ie/hse/bitstream/10147/51033/1/PracticeManagersBook08.pdf,

127. Walley T, Murphy M, Codd M, Johnston Z, Quirke T: Effects of a monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health board 1990–1995. Pharmacoepidemiol Drug Saf. 2000, 9 (7): 591-598. 10.1002/pds.544.

     CAS  Article  PubMed  Google Scholar 

128. Primary care: a new direction.//www.dohc.ie/publications/pdf/primcare.pdf?direct=1,

129. Harris CM, Scrivener G: Fundholders' Prescribing Costs: The First Five Years. BMJ: Brit Med J. 1996, 313 (7071): 1531-1534. 10.1136/bmj.313.7071.1531.

     CAS  Article  PubMed  PubMed Central  Google Scholar 

130. Pope ND: Generic Substitution of Narrow Therapeutic Index Drugs. US Pharmacist. 2009, 34 (6): 12-19. Generic Drug Review Supplement

     Google Scholar 

131. Okechukwu I, Bennett K, Feely J: General practitioners’ ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database. Br J Clin Pharmacol. 2006, 62 (2): 218-224. 10.1111/j.1365-2125.2006.02621.x.

     Article  PubMed  PubMed Central  Google Scholar 

Page 2

• Policies
• Accessibility
• Press center

• Support and Contact
• Leave feedback
• Careers

Follow BMC

• BMC Twitter page
• BMC Facebook page
• BMC Weibo page